1. Home
  2. TG vs VCRE Comparison

TG vs VCRE Comparison

Compare TG & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

SELL

Current Price

$7.73

Market Cap

239.6M

Sector

Industrials

ML Signal

SELL

Logo Vicore Pharma Holding AB American Depositary Shares

VCRE

Vicore Pharma Holding AB American Depositary Shares

HOLD

Current Price

$9.06

Market Cap

271.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
VCRE
Founded
1988
2000
Country
United States
Sweden
Employees
N/A
N/A
Industry
Metal Fabrications
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
239.6M
271.7M
IPO Year
1994
2026

Fundamental Metrics

Financial Performance
Metric
TG
VCRE
Price
$7.73
$9.06
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $29.16
AVG Volume (30 Days)
★ 174.6K
25.3K
Earning Date
11-06-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 151.06
N/A
EPS
★ 0.34
N/A
Revenue
★ $800,821,000.00
N/A
Revenue This Year
N/A
$101.29
Revenue Next Year
N/A
$481.15
P/E Ratio
$23.18
★ N/A
Revenue Growth
★ 8.29
N/A
52 Week Low
$6.25
$7.88
52 Week High
$10.53
$14.01

Technical Indicators

Market Signals
Indicator
TG
VCRE
Relative Strength Index (RSI) 64.33 40.94
Support Level $7.55 $8.34
Resistance Level $8.10 $12.08
Average True Range (ATR) 0.21 0.85
MACD 0.12 0.03
Stochastic Oscillator 79.13 26.70

Price Performance

Historical Comparison
TG
VCRE

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About VCRE Vicore Pharma Holding AB American Depositary Shares

Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.

Share on Social Networks: